William J. Febbo Buys 20,000 Shares of OptimizeRx Co. (NASDAQ:OPRX) Stock

OptimizeRx Co. (NASDAQ:OPRX) CEO William J. Febbo bought 20,000 shares of the stock in a transaction on Thursday, December 12th. The stock was acquired at an average cost of $5.01 per share, for a total transaction of $100,200.00. Following the acquisition, the chief executive officer now directly owns 601,253 shares in the company, valued at approximately $3,012,277.53. The trade was a 3.44 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

OptimizeRx Price Performance

NASDAQ:OPRX opened at $5.23 on Wednesday. The company has a market capitalization of $96.34 million, a price-to-earnings ratio of -3.93 and a beta of 1.34. The company has a 50-day moving average of $5.48 and a 200-day moving average of $7.92. OptimizeRx Co. has a 52 week low of $3.78 and a 52 week high of $16.65. The company has a debt-to-equity ratio of 0.29, a quick ratio of 3.23 and a current ratio of 3.23.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets grew its stake in shares of OptimizeRx by 189.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 3,690 shares of the company’s stock valued at $28,000 after purchasing an additional 2,414 shares during the period. Connors Investor Services Inc. grew its position in OptimizeRx by 15.1% in the second quarter. Connors Investor Services Inc. now owns 19,107 shares of the company’s stock valued at $191,000 after acquiring an additional 2,500 shares during the period. Summit Securities Group LLC bought a new stake in OptimizeRx in the second quarter valued at $25,000. Rhumbline Advisers lifted its holdings in shares of OptimizeRx by 9.2% during the second quarter. Rhumbline Advisers now owns 31,462 shares of the company’s stock valued at $315,000 after acquiring an additional 2,658 shares during the period. Finally, Greenwood Capital Associates LLC lifted its holdings in shares of OptimizeRx by 8.0% during the third quarter. Greenwood Capital Associates LLC now owns 67,356 shares of the company’s stock valued at $520,000 after acquiring an additional 4,999 shares during the period. Institutional investors own 76.47% of the company’s stock.

Analyst Ratings Changes

OPRX has been the topic of several research analyst reports. Stifel Nicolaus lowered their price objective on shares of OptimizeRx from $13.00 to $8.00 and set a “buy” rating on the stock in a research note on Thursday, November 14th. Royal Bank of Canada decreased their price target on shares of OptimizeRx from $14.00 to $7.00 and set an “outperform” rating on the stock in a research report on Thursday, November 14th. William Blair reaffirmed an “outperform” rating on shares of OptimizeRx in a research report on Thursday, November 14th. JMP Securities decreased their target price on OptimizeRx from $16.00 to $8.00 and set a “market outperform” rating on the stock in a research report on Thursday, November 14th. Finally, Barclays lowered their price target on OptimizeRx from $11.00 to $5.00 and set an “equal weight” rating on the stock in a research note on Thursday, November 14th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat, OptimizeRx currently has a consensus rating of “Moderate Buy” and an average price target of $10.42.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.